Summary
A mitomycin C (MMC)- and porfiromycin (PFM)-resistant subline of the HCT 116 human coloncancer cell line was isolated after repeated exposure of HCT 116 cells to increasing concentrations of MMC under aerobic conditions. The MMC-resistant subline (designated HCT 116-R30A) was 5 times more resistant than the parent cells to MMC and PFM under aerobic conditions. Both the MMC-resistant cells and the parent HCT 116 cells accumulated similar amounts of PFM by passive diffusion, but levels of macromolecule-bound PFM were about 50% lower in the resistant cell line, implying a decrease in PFM reductive activation in the resistant cells. The finding that microsomes from either sensitive or resistant cells showed an equal ability to reduce MMC and PFM indicated that the activity of NADPH cytochrome P-450 reductase (EC 1.6.2.4) was not changed in the resistant subline. Soluble extracts of HCT 116 cells reduced MMC and PFM more effectively at pH 6.1, and NADH and NADPH were utilized equally well as electron donors under both aerobic and anaerobic conditions. These data suggest that quinone reductase (EC 1.6.99.2; DT-diaphorase) in soluble extracts is responsible for the reduction of MMC. Quinone reductase activities in soluble extracts of HCT 116-R30A cells for the reduction of dichlorophenol indophenol (DCPIP) and menadione-cytochrome c at optimal pHs were decreased by 95% as compared with those obtained in parent cells. However, the MMC-reducing activity of HCT 116-R30A soluble extracts was only 50% lower than that of the parent cell extracts. The kinetic constants (K m, Vmax) found for quinone reductase in the two cell lines with respect to the substrates DCPIP and menadione differed. Two species of mRNA for quinone reductase (2.7 and 1.2 kb) were detected in both cell lines, and there was no detectable difference between parent and resistant cells in the steady-state level of either of these mRNA species. Furthermore, incubation with the quinone reductase inhibitor dicoumarol rendered HCT 116 cells more resistant to MMC. Alteration of the quinone reductase activity in HCT 116-R30A cells appears to be the mechanism responsible for their resistance to MMC and PFM.
Similar content being viewed by others
Abbreviations
- NAD(P)H:
-
reduced nicotinamide adenosine dinucleotide (phosphate)
- MMC:
-
mitomycin C
- PFM:
-
porfiromycin
- PBS:
-
phosphate-buffered saline
- DCPIP:
-
2,6-dichlorophenol indophenol
- DIC:
-
dicoumarol
- c- and t-AHME:
-
cis- andtrans-7-amino-1-hydroxyl-2-methoxyaminomitosene
- EDTA:
-
ethylenediaminetetraacetic acid
- AME:
-
7-aminio-2-methoxyaminomitosene
- DMSO:
-
dimethylsulfoxide
- SSC:
-
20xSSC contains 3m NaCl and 0.3m sodium citrat
- SSPE: 20xSSPE:
-
contains 3m NaCl, 0.2m monosodium phosphate, and 20mm EDTA
- SDS:
-
sodium dodecyl sulfate
References
Akman AS, Forrest G, Chu FF, Esworthy RS, Doroshow JH (1990) Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 50: 1397
Begleiter A, Robotham E, Lacey G, Leith MK (1989) Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett 45: 173
Chakrabarty S, Danels YJ, Long BH, Willson JKV, Brattain MG (1986) Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282. Cancer Res 46: 3456
Chou J, Chou TC (1985) Dose effect analysis with microcomputers. Elsevier, Amsterdam
Crooke ST (1979) Mitomycin C: an overview. In: Carter SK, Crooke ST (eds) Mitomycin C-current status and new developments. Academic Press, New York, p. 1
Doroshow JH (1981) Mitomycin C-enhanced superoxide and hydrogen peroxide formation in rat heart. J Pharmacol Exp Ther 218: 206
Dorr RT, Liddil JD, Trent JM, Dalton WS (1987) Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochem Pharmacol 36: 3115
Dulhanty AM, Whitmore GF (1991) Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 51: 1860
Ernster L (1967) DT diaphorase. Methods Enzymol 10: 309
Forrest GL, Qian J, Ma J, Kaplan WD, Akman S, Doroshow J, Chen S (1990) Rat liver NAD(P)H:quinone reductase: cDNA expression and site-directed mutations. Biochem Biophys Res Commun 169: 1087
Hissin PJ, Hilf R (1978) Characteristics of proline transport into R3230AC mammary tumor cells. Biochim Biophys Acta 508: 401
Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID (1990) Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res 50: 4691
Hodnick WF, Sartorelli AC (1991) Reductive activation of mitomycin C by NADH-cytochrome b reductase. Proc Am Assoc Cancer Res 32: 397
Jaiswal AK, McBride OW, Adesnik M, Nebert DW (1988) Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16. J Biol Chem 263: 13572
Kalyanaraman B, Perez-Reyes E, Mason RR (1980) Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 630: 119
Keyes SR, Rockwell S, Sartorelli AC (1985) Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res 45: 213
Komiyama T, Kikuchi T, Sugiura Y (1982) Generation of hydroxyl radical by anticancer quinone drugs carbazilquinone, mitomycin C, aclacinomycin A and Adriamycin in the presence of NADPH-cytochrome P-450 reductase. Biochem Pharmacol 31: 3651
Lenaz L (1985) Mitomycin C in advanced breast cancer. Cancer Treat Rev 12: 235
Long BH, Willson JKV, Brattain DE, Musial S, Brattain MG (1984) Effects of mitomycin on human colon carcinoma cells. J Natl Cancer Inst 73: 787
Lowry OH (1957) Micromethods for the assay of enzymes. Methods Enzymol 4: 366
MacDonald JS, Schein PS, Woolley PV, Smythe T et al. (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 9340: 533
Marshall RS, Paterson MC, Rauth AM (1989) Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br J Cancer 59: 341
Moertel CG, Reitemeier RJ, Hahn RG (1968) Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204: 1045
Musser SM, Pan S, Callery PS (1989) Liquid chromatograph-thermospray mass spectrometry of DNA adducts formed with mitomycin C, profiromycin and thiotepa. J Chromatogr 474: 197
Pan S, Iracki T (1988) Metabolites and DNA-adduct formation from flavoenzyme activated porfiromycin. Mol Pharmacol 34: 223
Pan S, Andrews P, Glover C, Bachur NR (1984) Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 259: 959
Pan S, Johnson R, Gonzelez H, Thohan V (1989) Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells. Cancer Res 49: 5048
Rockwell S, Kallman RF (1973) Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res 53: 281
Rockwell S, Keyes SR, Sartorelli AC (1988) Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro. Cancer Res 48: 5471
Rose WC, Huftalen JB, Bradner WT, Schurig E (1986) Characterization of P388 leukemia resistant to mitomycin C (MMC). Proc Am Assoc Cancer Res 27: 260
Sambrook J, Fritsch EF, Maniatis T (1989) Electrophoresis of RNA through gel containing formaldehyde. In: Ford N, Nolan C, Ferguson N (eds) Molecular cloning, a laboratory manual, (2nd edn), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Vol 1: 7.43
Schlager JJ, Powis G (1988) Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor) oxidoreductase. Cancer Chemother Pharmacol 22: 126
Siegel D, Gibson NW, Preusch PC, Ross D (1990) Metabolism of mitomycin C (MC) by DT-diaphorase (DTD): role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483
Siegel D, Gibson NW, Preusch PC, Ross D (1991) pH-Dependent metabolism of mitomycins by DT-diaphorase. Proc Am Assoc Cancer Res 32: 396
Steven CL, Taylor KG, Munk ME, Marshall WS, Noll K, Shal LG, Uzu K (1964) Chemistry and structure of mitomycin C. J Med Chem 8: 1
Tomasz M, Lipman R (1981) Reductive mechanism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry 20: 5056
Wallach DFH, Karmat VB (1966) Preparation of plasma-membrane fragments from mouse ascites tumor cells. Methods Enzymol 8: 164
Wermuth B, Platts KL, Seidel A, Oesch F (1986) Carbonyl reductase provides the enzymatic basis of quinone detoxification in man. Biochem Pharmacol 35: 1277
Willson JKV, Long BH, Marks ME, Brattain DE, Wiley JE, Brattain MG (1984) Mitomycin C resistance in a human colon carcinoma cell line associated with cell surface protein alterations. Cancer Res 44: 5880
Willson JKV, Chakrabarty S, Long BH, Brattain MG (1987) Deficient activation of mitomycin C in naive resistant human colon cancer cells. Proc Am Assoc Cancer Res 23: 286
Workman P, Walton MI, Powis G, Schlager JJ (1989) DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer 60: 800
Yasukochi Y, Masters BSS (1976) Some properties of detergentsolubilized NADPH-cytochrome C (cytochrome P-450) reductase purified by biospectific affinity chromatography. J Biol Chem 251: 5337
Author information
Authors and Affiliations
Additional information
This work was supported by grant CH-412 from the American Cancer Society and by an award from the Bressler Fund of the University of Maryland School of Medicine (to S. P.)
Rights and permissions
About this article
Cite this article
Pan, Ss., Akman, S.A., Forrest, G.L. et al. The role of NAD(P)H: quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother. Pharmacol. 31, 23–31 (1992). https://doi.org/10.1007/BF00695990
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00695990